Sarepta Therapeutics, Inc. (0L35.L)
USD 57.34
(-1.22%)
USD 57.34
(-1.22%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 968.37 Million USD | 48.85% |
| 2022 | 650.58 Million USD | 166.56% |
| 2021 | -977.48 Million USD | -127.43% |
| 2020 | -429.78 Million USD | -307.54% |
| 2019 | -105.46 Million USD | -312.09% |
| 2018 | 49.72 Million USD | 129.49% |
| 2017 | -168.64 Million USD | -58.69% |
| 2016 | -106.27 Million USD | -86.75% |
| 2015 | -56.9 Million USD | 15.35% |
| 2014 | -67.22 Million USD | 73.67% |
| 2013 | -255.29 Million USD | -37.33% |
| 2012 | -185.9 Million USD | -388.42% |
| 2011 | -38.06 Million USD | -20.2% |
| 2010 | -31.66 Million USD | 31.57% |
| 2009 | -46.27 Million USD | -407.53% |
| 2008 | -9.11 Million USD | 59.76% |
| 2007 | -22.66 Million USD | -12.41% |
| 2006 | -20.15 Million USD | 41.73% |
| 2005 | -34.59 Million USD | -107.73% |
| 2004 | -16.65 Million USD | -32.97% |
| 2003 | -12.52 Million USD | -20.61% |
| 2002 | -10.38 Million USD | 6.18% |
| 2001 | -11.06 Million USD | 57.26% |
| 2000 | -25.89 Million USD | -197.68% |
| 1999 | -8.7 Million USD | -2.35% |
| 1998 | -8.5 Million USD | 51.7% |
| 1997 | -17.6 Million USD | -486.67% |
| 1996 | -3 Million USD | -328.57% |
| 1995 | -700 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 952.05 Million USD | -1.69% |
| 2024 Q2 | 986.29 Million USD | 3.6% |
| 2023 Q1 | 416.54 Million USD | -35.97% |
| 2023 FY | 968.37 Million USD | 48.85% |
| 2023 Q4 | 968.37 Million USD | 16.73% |
| 2023 Q3 | 829.57 Million USD | 61.79% |
| 2023 Q2 | 512.75 Million USD | 23.1% |
| 2022 Q2 | 271.67 Million USD | 381.79% |
| 2022 Q3 | 539.37 Million USD | 98.54% |
| 2022 Q4 | 650.58 Million USD | 20.62% |
| 2022 FY | 650.58 Million USD | 166.56% |
| 2022 Q1 | -96.41 Million USD | 90.14% |
| 2021 Q4 | -977.48 Million USD | -121.77% |
| 2021 Q1 | -330.05 Million USD | 23.21% |
| 2021 Q2 | -539 Million USD | -63.31% |
| 2021 Q3 | -440.77 Million USD | 18.22% |
| 2021 FY | -977.48 Million USD | -127.43% |
| 2020 Q3 | -705.93 Million USD | 19.17% |
| 2020 FY | -429.78 Million USD | -307.54% |
| 2020 Q2 | -873.4 Million USD | 13.61% |
| 2020 Q4 | -429.78 Million USD | 39.12% |
| 2020 Q1 | -1.01 Billion USD | -858.65% |
| 2019 FY | -105.46 Million USD | -312.09% |
| 2019 Q2 | -327.34 Million USD | -28.74% |
| 2019 Q3 | -238.66 Million USD | 27.09% |
| 2019 Q4 | -105.46 Million USD | 55.81% |
| 2019 Q1 | -254.27 Million USD | -611.36% |
| 2018 FY | 49.72 Million USD | 129.49% |
| 2018 Q2 | 29.06 Million USD | 122.99% |
| 2018 Q1 | -126.42 Million USD | 25.03% |
| 2018 Q3 | 205.74 Million USD | 607.9% |
| 2018 Q4 | 49.72 Million USD | -75.83% |
| 2017 Q2 | -157.13 Million USD | 39.8% |
| 2017 Q1 | -261.03 Million USD | -145.63% |
| 2017 FY | -168.64 Million USD | -58.69% |
| 2017 Q4 | -168.64 Million USD | 71.24% |
| 2017 Q3 | -586.34 Million USD | -273.16% |
| 2016 Q1 | -17.02 Million USD | 70.08% |
| 2016 Q2 | -91.6 Million USD | -438.08% |
| 2016 Q3 | -376.54 Million USD | -311.06% |
| 2016 FY | -106.27 Million USD | -86.75% |
| 2016 Q4 | -106.27 Million USD | 71.78% |
| 2015 FY | -56.9 Million USD | 15.35% |
| 2015 Q3 | -32.53 Million USD | 25.86% |
| 2015 Q2 | -43.87 Million USD | 35.53% |
| 2015 Q1 | -68.05 Million USD | -1.24% |
| 2015 Q4 | -56.9 Million USD | -74.92% |
| 2014 FY | -67.22 Million USD | 73.67% |
| 2014 Q2 | -101.13 Million USD | -113.11% |
| 2014 Q3 | -46.02 Million USD | 54.49% |
| 2014 Q4 | -67.22 Million USD | -46.06% |
| 2014 Q1 | -47.45 Million USD | 81.41% |
| 2013 FY | -255.29 Million USD | -37.33% |
| 2013 Q3 | -271.95 Million USD | -76.05% |
| 2013 Q2 | -154.47 Million USD | 7.05% |
| 2013 Q1 | -166.18 Million USD | 10.61% |
| 2013 Q4 | -255.29 Million USD | 6.12% |
| 2012 Q4 | -185.9 Million USD | -413.42% |
| 2012 Q3 | -36.2 Million USD | -59.57% |
| 2012 Q2 | -22.69 Million USD | 21.08% |
| 2012 Q1 | -28.75 Million USD | 24.46% |
| 2012 FY | -185.9 Million USD | -388.42% |
| 2011 Q1 | -21.38 Million USD | 32.48% |
| 2011 Q2 | -52.3 Million USD | -144.64% |
| 2011 Q3 | -44.49 Million USD | 14.93% |
| 2011 Q4 | -38.06 Million USD | 14.46% |
| 2011 FY | -38.06 Million USD | -20.2% |
| 2010 Q1 | -38.34 Million USD | 17.13% |
| 2010 FY | -31.66 Million USD | 31.57% |
| 2010 Q3 | -34.02 Million USD | 2.17% |
| 2010 Q4 | -31.66 Million USD | 6.93% |
| 2010 Q2 | -34.78 Million USD | 9.31% |
| 2009 Q3 | -48.24 Million USD | -176.93% |
| 2009 Q4 | -46.27 Million USD | 4.08% |
| 2009 Q2 | -17.42 Million USD | 21.31% |
| 2009 Q1 | -22.13 Million USD | -142.79% |
| 2009 FY | -46.27 Million USD | -407.53% |
| 2008 Q2 | -16.4 Million USD | 8.04% |
| 2008 Q1 | -17.83 Million USD | 21.29% |
| 2008 Q4 | -9.11 Million USD | 23.97% |
| 2008 Q3 | -11.99 Million USD | 26.89% |
| 2008 FY | -9.11 Million USD | 59.76% |
| 2007 Q2 | -7.08 Million USD | 52.64% |
| 2007 Q4 | -22.66 Million USD | -1231.25% |
| 2007 FY | -22.66 Million USD | -12.41% |
| 2007 Q1 | -14.96 Million USD | 25.77% |
| 2007 Q3 | -1.7 Million USD | 75.98% |
| 2006 Q4 | -20.15 Million USD | 21.19% |
| 2006 Q3 | -25.57 Million USD | 19.48% |
| 2006 Q1 | -36.86 Million USD | -6.56% |
| 2006 FY | -20.15 Million USD | 41.73% |
| 2006 Q2 | -31.76 Million USD | 13.84% |
| 2005 Q3 | -27.55 Million USD | -0.77% |
| 2005 Q1 | -34.35 Million USD | -106.29% |
| 2005 Q4 | -34.59 Million USD | -25.55% |
| 2005 FY | -34.59 Million USD | -107.73% |
| 2005 Q2 | -27.34 Million USD | 20.41% |
| 2004 Q4 | -16.65 Million USD | -34.95% |
| 2004 FY | -16.65 Million USD | -32.97% |
| 2004 Q2 | -11.04 Million USD | -27.14% |
| 2004 Q3 | -12.34 Million USD | -11.74% |
| 2004 Q1 | -8.68 Million USD | 30.64% |
| 2003 FY | -12.52 Million USD | -20.61% |
| 2003 Q4 | -12.52 Million USD | -91.81% |
| 2003 Q3 | -6.53 Million USD | 28.07% |
| 2003 Q2 | -9.07 Million USD | -26.59% |
| 2003 Q1 | -7.17 Million USD | 30.94% |
| 2002 Q2 | -13.44 Million USD | 55.01% |
| 2002 FY | -10.38 Million USD | 6.18% |
| 2002 Q1 | -29.88 Million USD | -169.98% |
| 2002 Q3 | -12.58 Million USD | 6.37% |
| 2002 Q4 | -10.38 Million USD | 17.51% |
| 2001 Q4 | -11.06 Million USD | 55.03% |
| 2001 Q1 | -22 Million USD | 15.05% |
| 2001 Q3 | -24.61 Million USD | 12.51% |
| 2001 Q2 | -28.13 Million USD | -27.86% |
| 2001 FY | -11.06 Million USD | 57.26% |
| 2000 Q1 | -9.58 Million USD | -10.12% |
| 2000 Q3 | -29.55 Million USD | -325.3% |
| 2000 Q2 | -6.94 Million USD | 27.46% |
| 2000 FY | -25.89 Million USD | -197.68% |
| 2000 Q4 | -25.89 Million USD | 12.37% |
| 1999 FY | -8.7 Million USD | -2.35% |
| 1999 Q1 | -6.7 Million USD | 21.18% |
| 1999 Q4 | -8.7 Million USD | -262.5% |
| 1999 Q2 | -4.4 Million USD | 34.33% |
| 1999 Q3 | -2.4 Million USD | 45.45% |
| 1998 Q2 | -13.2 Million USD | 16.46% |
| 1998 Q3 | -10.9 Million USD | 17.42% |
| 1998 FY | -8.5 Million USD | 51.7% |
| 1998 Q1 | -15.8 Million USD | 10.23% |
| 1998 Q4 | -8.5 Million USD | 22.02% |
| 1997 Q3 | -18.5 Million USD | -5.11% |
| 1997 Q2 | -17.6 Million USD | -665.22% |
| 1997 FY | -17.6 Million USD | -486.67% |
| 1997 Q1 | -2.3 Million USD | 23.33% |
| 1997 Q4 | -17.6 Million USD | 4.86% |
| 1996 FY | -3 Million USD | -328.57% |
| 1996 Q4 | -3 Million USD | 0.0% |
| 1995 FY | -700 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 1040.62% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 3202.085% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -388.919% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -2937.096% |
| bluebird bio, Inc. | 108.57 Million USD | -791.931% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 10840.661% |
| Imunon, Inc. | -4.69 Million USD | 20706.975% |
| Editas Medicine, Inc. | -87.11 Million USD | 1211.596% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 92.467% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 53.842% |
| Myriad Genetics, Inc. | 88.1 Million USD | -999.18% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -446.18% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 2988.353% |
| Verastem, Inc. | -37.27 Million USD | 2697.72% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 88.241% |
| Waters Corporation | 1.96 Billion USD | 50.604% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 96.392% |
| Biogen Inc. | 6.28 Billion USD | 84.6% |
| Nektar Therapeutics | 210.24 Million USD | -360.606% |
| Perrigo Company plc | 3.32 Billion USD | 70.85% |
| Dynavax Technologies Corporation | 106.63 Million USD | -808.124% |
| Illumina, Inc. | 1.21 Billion USD | 20.232% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -13797.351% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 950.29% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -567.497% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -13374.023% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -155.679% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 13739.127% |
| Evolus, Inc. | 63.7 Million USD | -1420.026% |
| Adicet Bio, Inc. | -142 Million USD | 781.918% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 2731.176% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 3673.351% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -111.114% |
| FibroGen, Inc. | 56.76 Million USD | -1605.882% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 15.426% |
| OPKO Health, Inc. | 230.68 Million USD | -319.787% |
| Homology Medicines, Inc. | 18.43 Million USD | -5152.362% |
| Geron Corporation | 14.76 Million USD | -6460.382% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 38.916% |
| Exelixis, Inc. | -73.05 Million USD | 1425.637% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 1884.831% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 741.208% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 969.264% |
| Zoetis Inc. | 4.76 Billion USD | 79.664% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 584.623% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 9715.51% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 110.125% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 6745.471% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 8.147% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 815.198% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 29.872% |
| Blueprint Medicines Corporation | 702.83 Million USD | -37.782% |
| Insmed Incorporated | 721.62 Million USD | -34.195% |
| TG Therapeutics, Inc. | 17.86 Million USD | -5321.442% |
| Incyte Corporation | -3.17 Billion USD | 130.499% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -26.453% |